Recent Updates
Recently added Catalysts
ABSI Positive Sentiment

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Wednesday, June 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Absci has announced the pricing of a $100 million underwritten offering, attracting investments from notable firms including Eli Lilly & Company and Adage. The funds will be utilized to further develop ABS-201, a treatment targeting androgenetic alopecia and endometriosis. This investment reflects strong confidence in Absci's potential in the biopharma sector.
Price reaction · baseline $7.41 (2026-06-23 close) · hit pre-market · clean, no other ABSI news in the window
day 0 close
+36%
day 1
+37.8%
day 3 · peak
+53.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Absci successfully secured $100 million in funding.
  • Investment from reputable firms indicates strong confidence in Absci.
  • Proceeds will support advancement of ABS-201 for important indications.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+405%
120-day peak, hindsight
Typical move
13.1%
average across 4 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
ABS-201
Phase 1 · Androgenetic Alopecia (AGA)

Full Press Release Details

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis VANCOUVER, Wash.

Frequently Asked Questions

What is the amount raised by Absci?

Absci raised $100 million through an underwritten offering.

Who are the investors in Absci's offering?

Investors include Eli Lilly, Adage, BVF Partners, and others.

What will the funds be used for?

The funds will support the advancement of ABS-201 for specific conditions.

What conditions does ABS-201 target?

ABS-201 targets androgenetic alopecia and endometriosis.

ShareAdd on Google
Tags: ABSI Viatris Investor Conferences Healthcare Absci ABS-201 Eli Lilly androgenetic alopecia endometriosis
Last updated: Jun 24, 2026

Biotech snapshot

Cash runway
$201M liquidity · $9M/mo burn
~21 mo
Low dilution risk
Lead asset
ABS-201Phase 1
Androgenetic Alopecia (AGA) →

Catalyst track record

+405%
best trade around ABSI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ABSI.

See every catalyst's timing & PoA →